Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 17/20 | 0.49 |
| ▸ | DDB1 | Q16531 | 16/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | GSPT1 | P15170 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31161726 | 0.89 | DDB1 (0.50) | CRBNDDB1TSHRIKZF3GSPT1 | |
| SCHEMBL31161802 | 0.85 | SLC6A2 (0.47) | CRBNDDB1TSHRSLC6A4SLC6A2 | |
| SCHEMBL30158164 | 0.84 | CRBN (0.49) | CRBNDDB1IKZF3 | |
| SCHEMBL25240043 | 0.84 | CRBN (0.49) | CRBNDDB1IKZF3 | |
| SCHEMBL30984703 | 0.81 | CRBN (0.48) | CRBNDDB1TSHR | |
| SCHEMBL29348720 | 0.79 | CRBN (0.49) | CRBNDDB1 | |
| SCHEMBL25920712 | 0.79 | CRBN (0.56) | CRBNDDB1 | |
| SCHEMBL27119032 | 0.77 | CRBN (0.68) | CRBNDDB1GSPT1 | |
| SCHEMBL23115228 | 0.76 | DDB1 (0.44) | CRBNDDB1IKZF3 | |
| SCHEMBL25905898 | 0.76 | CRBN (0.49) | CRBNDDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124309-A1 | STAT6 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260125400-A1 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| WO-2025049820-A1 | STAT6 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2025-03-06 | — | — | WO | disclosed |
| WO-2024220937-A2 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2024-10-24 | — | — | WO | disclosed |
| WO-2024146502-A1 | WEE1 DEGRADING COMPOUNDS | BEIJING NEOX BIOTECH LIMITED (CN) | 2024-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125400-A1 | TYK2 DEGRADERS AND USES THEREOF | TYK2, CSNK2A1, CSNK2A2 | CRBN 91/4885DDB1 3238/4885TSHR 256/4885 |
| US-20260124309-A1 | STAT6 DEGRADERS AND USES THEREOF | STAT6, NCOR2, NCOR1 | CRBN 207/4885DDB1 3932/4885TSHR 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.